elafibranor   Click here for help

GtoPdb Ligand ID: 11135

Synonyms: GFT-505 | GFT505 | Iqirvo®
Approved drug PDB Ligand
elafibranor is an approved drug (EMA & FDA (2024))
Compound class: Synthetic organic
Comment: Elafibranor (GFT-505) is a PPARα/δ agonist.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 88.9
Molecular weight 384.14
XLogP 4.97
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CSc1ccc(cc1)C(=O)/C=C/c1cc(C)c(c(c1)C)OC(C(=O)O)(C)C
Isomeric SMILES CSc1ccc(cc1)C(=O)/C=C/c1cc(C)c(c(c1)C)OC(C(=O)O)(C)C
InChI InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
InChI Key AFLFKFHDSCQHOL-IZZDOVSWSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

Bioactivity Comments
GFT-505 had beneficial effects preclinically, including reduction of hepatic fat accumulation, inflammation and fibrosis, which confirmed it as a promising candidate for the treatment of NAFLD/nonalcoholic steatohepatitis (NASH). GFT-505 is converted to its main active metabolite, GFT-1007 in the liver.
Selectivity at nuclear hormone receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Peroxisome proliferator-activated receptor-α Hs Agonist Agonist 8.2 pEC50 - 4
pEC50 8.2 (EC50 6x10-9 M) [4]
Peroxisome proliferator-activated receptor-γ Hs Agonist Agonist 7.3 pEC50 - 4
pEC50 7.3 (EC50 4.7x10-8 M) [4]